Mucormycosis in organ and stem cell transplant recipients
Journal
Clinical Infectious Diseases
Journal Volume
54
Journal Issue
11
Pages
1629-1636
Date Issued
2012
Author(s)
Abstract
Mucormycosis is a devastating invasive fungal disease whose incidence has increased during the past decade. Mucormycosis now represents a major threat in transplant recipients, accounting for 2% and 8% of invasive fungal infections in recent cohorts of solid-organ and allogeneic stem-cell transplant recipients, respectively. Mucormycosis most often occurs late, >3 months after transplantation, although cases occurring early have been observed, especially among liver transplant recipients and in cases of graft-transmitted infection. Recent guidelines have emphasized the direct examination of the involved fluid or tissue and culture from a sterile site as the most appropriate diagnostic strategy and the use of lipid formulations of amphotericin B and major surgery when feasible as the most appropriate first-line therapeutic strategy for mucormycosis in organ and stem cell transplant recipients. ? 2012 The Author.
SDGs
Other Subjects
amphotericin B lipid complex; cyclosporin; fluconazole; immunosuppressive agent; polyene; posaconazole; rapamycin; steroid; tacrolimus; voriconazole; article; clinical feature; computer assisted tomography; diagnostic procedure; disease course; disease severity; fungus culture; graft infection; graft recipient; graft versus host reaction; human; immune status; incidence; infection risk; Mucor; mucormycosis; nonhuman; outcome assessment; postoperative period; practice guideline; priority journal; randomized controlled trial (topic); Rhizopus; sex difference; survival rate; treatment indication; Amphotericin B; Antifungal Agents; Body Fluids; Humans; Immunocompromised Host; Incidence; Mucorales; Mucormycosis; Organ Transplantation; Stem Cell Transplantation; Transplantation
Type
journal article